GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Download PDF Copy

Editorial Checklist

Reviewed

Industrial Info ResourcesDec 4 2009

NewsGuard 100/100 Score

Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc (NYSE:GSK) (Middlesex, England) has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure. The batch comprised 172,000 doses of the drug and had been distributed to health agencies in the provinces of Alberta, British Columbia, Manitoba, Ontario, Prince Edward Island and Saskatchewan.

Source:

Industrial Info Resources

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Allergy, GlaxoSmithKline, H1N1, Public Health, Vaccine

Comments (0)

Download PDF Copy

Suggested Reading

New nasal vaccine could help stop the spread of whooping cough

New nasal vaccine could help stop the spread of whooping cough

Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17

Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Community partnerships lead to more inclusive health care for neurodiverse individuals

Community partnerships lead to more inclusive health care for neurodiverse individuals

Innovative vaccine shields livestock from four strains of foot and mouth disease

Innovative vaccine shields livestock from four strains of foot and mouth disease

Public trust in COVID-19 vaccine science influences vaccine uptake in the US

Public trust in COVID-19 vaccine science influences vaccine uptake in the US

WHO grants Emergency Use Listing for LC16m8 mpox vaccine

WHO grants Emergency Use Listing for LC16m8 mpox vaccine

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New vaccine shows potential in preventing recurrence of triple-negative breast cancer